Microbot Medical (MBOT) Expected to Announce Quarterly Earnings on Wednesday

Posted by George Bondi on May 6th, 2026

Microbot Medical (NASDAQ:MBOT – Get Free Report) is projected to release its results after the market closes on Wednesday, May 13th. Analysts expect Microbot Medical to post earnings of ($0.08) per share and revenue of $0.30 million for the quarter.

Microbot Medical (NASDAQ:MBOT – Get Free Report) last announced its quarterly earnings data on Friday, March 27th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. On average, analysts expect Microbot Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Microbot Medical Stock Performance

NASDAQ MBOT opened at $2.10 on Wednesday. The firm has a 50-day simple moving average of $2.41 and a 200 day simple moving average of $2.23. Microbot Medical has a twelve month low of $1.60 and a twelve month high of $4.67. The stock has a market cap of $141.04 million, a PE ratio of -7.24 and a beta of 1.06.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Microbot Medical in a report on Tuesday, April 14th. B. Riley Financial initiated coverage on Microbot Medical in a report on Tuesday, February 10th. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research report on Friday, April 10th. Finally, Wall Street Zen lowered Microbot Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.50.

Read Our Latest Stock Report on MBOT

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in Microbot Medical during the fourth quarter worth about $117,000. Invesco Ltd. bought a new stake in shares of Microbot Medical in the 4th quarter valued at approximately $49,000. XTX Topco Ltd acquired a new position in shares of Microbot Medical in the 4th quarter worth approximately $63,000. Man Group plc acquired a new position in shares of Microbot Medical in the 4th quarter worth approximately $35,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Microbot Medical during the 4th quarter worth approximately $222,000. Institutional investors and hedge funds own 16.30% of the company’s stock.

Microbot Medical Company Profile

(Get Free Report)

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.